Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study - PubMed
4 hours ago
- #Diabetes
- #Combination Therapy
- #Clinical Trial
- CagriSema, a combination of cagrilintide and semaglutide, demonstrated superior HbA1c reduction compared to semaglutide alone in a phase 3 trial for type 2 diabetes.
- The study involved 2,713 participants with overweight or obesity and inadequately controlled diabetes, randomized to various treatment groups including combination therapy and monotherapies.
- The primary endpoint showed a greater mean HbA1c change with CagriSema (2.4 mg each) versus semaglutide 2.4 mg, with a statistically significant estimated treatment difference.
- Safety data indicated adverse events, primarily gastrointestinal disorders, were common across active treatment groups but consistent with the known profiles of GLP-1 receptor agonists.
- The trial supports the added benefit of the combination therapy for glycemic control in this patient population, with funding and conflicts of interest disclosed, primarily involving Novo Nordisk.